
Las acciones de Novo Nordisk suben tras un sólido lanzamiento de la píldora Wegovy
Novo Nordisk shares moved higher after early U.S. prescription figures signaled a stronger-than-expected market entry for its oral Wegovy obesity treatment, reinforcing investor confidence in the company’s strategy to expand beyond injectable GLP-1 drugs. The launch marks a critical inflection point as demand for obesity therapies continues to accelerate across











